RxDoctor Payments Data

Alexander Malone, MD

Otolaryngology · Clearwater, FLNPI 1558603613

Payments from drug & device makers

$3,203in general payments, 2019–2025

Across 101 payments — averaging $31.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$780
  • Sanofi$602
  • Optinose US, Inc.$442
  • Cochlear Americas$254
  • GSK$238
  • Biohaven Pharmaceuticals, Inc.$124
  • plus $763 from 15 others

What the payments were for

  • Food & beverage$3,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,203 in reported general payments places this provider in the 65th percentile of 586 otolaryngology providers in Florida.

See all otolaryngology providers in Florida

Medicare billing

Part B allowed, 2024
$106,778
Medicare patients
260
Services billed
2,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate18$12,231
Azelastine Hcl479$11,801
Epinephrine42$8,234
Fluticasone Propionate371$4,760
Fluocinolone Acetonide Oil110$4,418
Ofloxacin65$2,363
Scopolamine17$2,039
Ciprofloxacin Hcl46$1,782
Fluticasone Propionate HfaFluticasone Propionate11$1,768
Ipratropium Bromide52$1,698
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort25$1,675
Pantoprazole Sodium143$829
Levocetirizine Dihydrochloride70$690
Mupirocin64$449
Methylprednisolone53$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$442$12,23118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 586 otolaryngology providers in Florida.

Other otolaryngology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →